Japan approves Keytruda plus Lenvima combination for endometrial cancer treatment
the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Keytruda plus Lenvima combination to treat endometrial carcinoma.
December 28, 2021
by drugs
European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma
Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance...
December 2, 2021
by AmericanPharmaceuticalReview
EC grants approval for Merck-Eisai’s combo therapy for endometrial cancer
The European Commission (EC) has granted approval for Merck (MSD) and Eisai’s Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) to treat adults with advanced or recurrent endometrial cancer.
December 1, 2021
by Pharmaceutical-Technology
FDA approves Keytruda plus Lenvima for advanced kidney cancer
The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult patients with advanced renal cell carcinoma ...
August 13, 2021
by pharmatimes
US clears Keytruda, Lenvima combo in first-line kidney cancer
The FDA announced Wednesday that it approved the combination of Merck & Co.'s anti-PD-1 therapy Keytruda (pembrolizumab) and Eisai's oral multi-kinase inhibitor Lenvima (lenvatinib) as a first-line treatment for adults with advanced renal cell carcinoma.
August 12, 2021
by firstwordpharma
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima.
July 29, 2021
by drugs
Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
July 26, 2021
by contractpharma
Eisai’s anti-cancer agent LENVIMA receives orphan drug designation
Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer.
March 16, 2021
by pharmaceutical-technology
Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial
Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai ..
December 21, 2020
by pharmaceutical-business-review
Lenvima plus Keytruda achieves primary endpoints in trial for RCC
Lenvima and Keytruda has demonstrated positive top-line results in a Phase III trial in patients with advanced renal cell carcinoma.
November 12, 2020
by europeanpharmaceuticalreview
Keytruda/Lenvima combo shows promise in hard-to-treat cancers
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
September 22, 2020
by pharmatimes
US rejects MSD/Eisai's Keytruda Lenvima combo
MSD and Eisai have received a complete response letter (CRL) from the US Food and Drug Administration rejecting accelerated approval of a combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for liver cancer.
July 10, 2020
by pharmatimes